Eli Lilly and Company logo

Eli Lilly and Company LLY

$ 754.63 3.41%

Quarterly report 2024-Q3
added 10-30-2024

report update icon

Country

usaUSA

IPO year

-

Industry

Biotechnology

Stock Exchange

NYSESPB

CEO

Mr. David Ricks

Employees in the company

35 065

Shares

900 M

Market Cap[1]

$ 679 B

EBITDA (LTM)

$ 2.35 B

P/E (LTM)

124.53

P/S (LTM)

18.59

EPS (LTM)

6.8

Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.

The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.

One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.

Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.

Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.11 35.12 % $ 105 M Nasdaq Global Market usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.41 -5.36 % $ 43.9 M Nasdaq Global Market usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 1.48 -7.22 % $ 8.2 M Nasdaq Capital Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.4 -5.8 % $ 105 M Nasdaq Global Select Market,SPB usaUSA
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 12.18 1.42 % $ 1.57 B Nasdaq Capital Market usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B Nasdaq Global Market,SPB usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M Nasdaq Capital Market usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.